Human Genome Sciences, Inc.'s Lupus Drug Draws Questions; FDA Forms Advisory Committee

WASHINGTON, Nov 12 (Reuters) - U.S. drug reviewers questioned if the benefits of a long-awaited Human Genome Sciences Inc (HGSI.O) lupus drug outweighed concerns about suicide and other possible risks, but analysts said they still expected approval.